Electromed

ELMD

Market cap $334M

LQDA, FLXS, ELMD and AGX combine low beta, positive price momentum and strong fundamentals to help investors navigate market volatility.

Electromed (ELMD) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

If you are looking for stocks that are well positioned to maintain their recent uptrend, Electromed (ELMD) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Electromed is rated 'buy' due to accelerating growth, margin expansion, and a large underpenetrated bronchiectasis market. ELMD benefits from a new CMS rule and a recently approved bronchiectasis drug, both driving increased disease awareness and streamlined clinician adoption. Gross margin improved to 78.5%, operating margin rose to 20.4%, and net income reached a record $3.0 million in Q3 FY 2026.

Electromed (ELMD) is well positioned to outperform the market, as it exhibits above-average growth in financials.

GOLD, ELMD and TPR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 2nd, 2026.

GOLD, ELMD, TPR, PLGO and CRGY have been added to the Zacks Rank #1 (Strong Buy) List on June 2nd, 2026.

Electromed (ELMD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

GenAI is reshaping medical instruments as Electromed, Globus Medical and Intuitive Surgical navigate M&A and market pressures.

Electromed, Inc. (ELMD) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ELMD's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.